Development of radiopharmaceuticals targeting GRPR in PC has gained increasing interest in the effort to improve the diagnostic accuracy by detection of metastases and to develop new treatment strategies [37,38,39]. The gene discussed is GRPR; the disease is pachyonychia congenita.